Core Insights - The medical services sector experienced a rise of 1.67% on October 31, with Haitai Biological leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Services Sector Performance - Haitai Biological (300683) closed at 34.46, up 11.20% with a trading volume of 158,200 shares and a transaction value of 530 million [1] - Other notable performers included: - Nanmo Biological (688265) at 50.60, up 9.98% [1] - Nuo Si Ge (301333) at 68.59, up 7.00% [1] - Yangguang Nuohe (688621) at 58.75, up 5.10% [1] - *ST Biological (000504) at 9.57, up 5.05% [1] Capital Flow Analysis - The medical services sector saw a net inflow of 461 million from institutional investors, while retail investors experienced a net inflow of 918,230 [2] - Notable capital flows included: - Innovation Medical (002173) with a net inflow of 14.416 million from institutional investors [3] - Tai Ge Medical (300347) with a net inflow of 70.6534 million from institutional investors [3] - Zhaoyan New Drug (603127) with a net inflow of 53.6731 million from institutional investors [3]

一、股票交易异常波动的具体情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"） 股票于 2025 年 10 月 29 日、2025 年 10 月 30 日、2025 年 10 月 31 日连续三个交易日收盘价 格涨幅偏离值累计超过 30%，根据《深圳证券交易所交易规则》的相关规定，属 于股票交易异常波动的情况。 二、说明关注、核实情况 证券代码：301333 证券简称：诺思格 公告编号：2025-049 诺思格（北京）医药科技股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 三、不存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所创业板股票 上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、 意向、协议等；董事会也未获悉本公司有根据《深圳证券交易所创业板股票上市 规则》等有关规定应予以披露而未披露的、对本公司股票及其衍生品种交易价格 产生较大影响的信息；公司前期披露的信息不存在需要更正、补充之处。 四、风险提示 针对公司股票交易异常波动情况，公司董事会对公司、控 ...

证券代码：301333 证券简称：诺思格 公告编号：2025-048 诺思格（北京）医药科技股份有限公司 2025 年员工持股计划第一次持有人会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、持有人会议召开情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"）2025年员工持 股计划第一次持有人会议（以下简称"本次会议"）于2025年10月31日在公司会 议室以现场结合通讯方式召开。本次会议由董事会秘书李树奇先生主持。出席本 次会议的持有人共35人，代表2025年员工持股计划份额1,499.9904万份，占公司 2025年员工持股计划已认购总份额的100%。会议的召集、召开和表决程序符合 相关法律法规、规范性文件及公司《2025年员工持股计划（草案）》《2025年员工 持股计划管理办法》的规定。 二、持有人会议审议情况 表决结果：同意 1,499.9904 万份，占出席持有人会议的持有人所持份额总数 的 100%，反对 0 份，弃权 0 份。 为保证员工持股计划的顺利进行，保障持有人的合法权益，根据公司《2025 年员工持股计划管理办法》 ...

Core Viewpoint - The company reported steady revenue growth and exceeded profit expectations in Q3 2025, driven by a low base from the previous year and a higher number of project settlements [1][2][3]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 607 million, a year-on-year increase of 8.09%, and a net profit attributable to shareholders of 96 million, up 13.21%. The net profit after deducting non-recurring items was 81 million, reflecting a growth of 22.47% [1]. - In Q3 2025 alone, the company recorded revenue of 228 million, representing a year-on-year growth of 24.48%. The net profit attributable to shareholders was 34 million, up 32.98%, while the net profit after deducting non-recurring items reached 30 million, marking a significant increase of 52.69% [2]. - The gross profit margin for the first three quarters was 35.61%, down 3.58 percentage points year-on-year, while the net profit margin increased by 0.65 percentage points to 15.94%. Management and sales expense ratios improved, with management expenses at 10.07% (down 5.11 percentage points) and sales expenses at 1.66% (down 0.24 percentage points) [2]. Industry Outlook - The onset of a rate-cutting cycle by the Federal Reserve, with a 25 basis point cut in September 2025 and expectations for further cuts, is anticipated to gradually revive investment and financing, benefiting the clinical CRO sector [3]. - The introduction of domestic innovative drug support policies is expected to favor local clinical CROs, positioning the company for rapid growth opportunities [3]. Profit Forecast and Investment Recommendation - Revenue projections for 2025-2027 are estimated at 776 million, 852 million, and 969 million, with year-on-year growth rates of 4.33%, 9.75%, and 13.79%, respectively. Net profit attributable to shareholders is forecasted at 150 million, 163 million, and 181 million, with growth rates of 6.85%, 8.83%, and 11.26% [3]. - The company is assigned a "buy" rating with corresponding price-to-earnings ratios of 33, 31, and 28 for the years 2025, 2026, and 2027 [3].

Core Viewpoint - Norsg achieved a daily limit increase of 20.00%, with a turnover rate of 16.62% and a transaction volume of 558 million yuan, indicating strong market interest and activity in the stock [2] Trading Activity - Institutional investors net bought 66.92 million yuan, while brokerage seats collectively net sold 28.46 million yuan on the same day [2] - The top five trading departments accounted for a total transaction volume of 147 million yuan, with a net buying amount of 38.46 million yuan [2] - Specific institutional buying included amounts of 27.01 million yuan, 20.58 million yuan, 19.03 million yuan, and 12.40 million yuan from various specialized seats [2] Fund Flow - The stock saw a net inflow of 66.37 million yuan from major funds, with a significant inflow of 74.26 million yuan from large orders, while smaller orders experienced a net outflow of 7.89 million yuan [2] - Over the past five days, the net inflow of major funds totaled 74.31 million yuan, indicating a positive trend in investor sentiment [2]

Core Points - The Shanghai Composite Index closed at 4016.33 points, above the six-month moving average, with an increase of 0.70% [1] - The total trading volume of A-shares reached 22,906.74 billion yuan [1] - A total of 145 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Notable stocks with high deviation rates include: - Digital Human: 20.14% deviation, closing price of 18.47 yuan, with a daily increase of 29.98% and a turnover rate of 26.73% [1] - Weston: 19.60% deviation, closing price of 61.52 yuan, with a daily increase of 19.99% and a turnover rate of 48.37% [1] - Norsg: 19.43% deviation, closing price of 61.92 yuan, with a daily increase of 20.00% and a turnover rate of 16.62% [1] Other Stocks - Stocks with smaller deviation rates that just crossed the six-month line include: - Vatti: minimal deviation, closing price of 7.99 yuan, with a daily increase of 7.97% [1] - ST Huake: minimal deviation, closing price of 6.19 yuan, with a daily increase of 6.17% [1] - Lisheng Pharmaceutical: minimal deviation, closing price of 6.51 yuan, with a daily increase of 11.09% [1]

Core Points - The Shanghai Composite Index closed at 4001.98 points, above the six-month moving average, with a gain of 0.35% [1] - The total trading volume of A-shares reached 183.41 billion yuan [1] - A total of 90 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The stocks with the highest deviation rates include: - Weston (威士顿) with a deviation rate of 19.60% and a price increase of 19.99% [1] - Norsg (诺思格) with a deviation rate of 19.43% and a price increase of 20.00% [1] - Digital China (神州数码) with a deviation rate of 7.79% and a price increase of 7.88% [1] - Other stocks with smaller deviation rates that just crossed the six-month line include: - Baiyunshan (白云山) and Yuhuan CNC (宇环数控) [1] Trading Data - The trading turnover for the day was 18340.64 million yuan [1] - The stocks listed showed varying turnover rates, with Weston at 47.99% and Norsg at 15.54% [1] Additional Stock Information - Other notable stocks with significant price movements include: - Changqing (长青股份) with a price increase of 9.97% and a deviation rate of 7.77% [1] - Jinko Solar (晶科能源) with a price increase of 7.01% and a deviation rate of 6.82% [1] - The table provided lists various stocks, their trading performance, and deviation rates, indicating a diverse range of market activity [1][2]

Group 1 - The core viewpoint of the article highlights a significant rise in innovative pharmaceutical stocks, with notable gains in specific companies [1] Group 2 - Norska has reached a 20% limit up, indicating strong market interest and investor confidence [1] - Puris and Kangzhi Pharmaceutical have both increased by over 10%, reflecting positive market sentiment towards these companies [1] - Other companies such as Tigermed, Kanglong Chemical, and Betta Pharmaceuticals are also showing substantial gains, contributing to the overall bullish trend in the sector [1]

Group 1 - The core viewpoint of the news is that as of October 28, 2025, institutional investors hold a significant portion of Northstar's A-shares, totaling 71.78 million shares, which represents 74.32% of the company's total equity [1] - The top ten institutional investors collectively own 72.43% of the shares, with an increase of 2.73 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one public fund, Hongta Hongtu Medical Selected Stock Initiation A, increased its holdings slightly, while two new public funds disclosed their holdings, including Nuoan Pioneer Mixed A and Xin'ao Enjoy Life Mixed A [2] - The social security fund sector saw an increase in holdings from the National Social Security Fund 413 Combination, with a holding increase of 0.80%, and one new disclosure from the National Social Security Fund 601 Combination [2] - In terms of foreign investment, there was one foreign institution, Hong Kong Central Clearing Limited, that did not disclose its holdings in the current period [2]

Core Insights - The company reported a revenue of 227,707,628.96 yuan for the third quarter of 2025, representing a year-on-year growth of 24.48% [2] - The net profit attributable to shareholders of the listed company was 34,450,734.90 yuan, showing a year-on-year increase of 32.98% [2] Financial Performance - Revenue for Q3 2025: 227.71 million yuan, up 24.48% year-on-year [2] - Net profit for Q3 2025: 34.45 million yuan, up 32.98% year-on-year [2]